News - Vertex

Filter

Current filters:

Vertex

Popular Filters

1 to 25 of 41 results

FDA backs Kalydeco for eight additional mutations that cause cystic fibrosis

22-02-2014

The US Food and Drug Administration approved biotech firm Vertex Pharmaceuticals’ supplemental New…

BiotechnologyKalydecoNorth AmericaRare diseasesRegulationUSAVertex

Vertex sells Incivo royalty rights to Janssen for $152 million

21-11-2013

Loss-making US biotech firm Vertex Pharmaceuticals says that it has sold its product royalty rights relating…

Anti-viralsBiotechnologyFinancialIncivoJanssenJohnson & JohnsonLicensingVertex

Vertex outlines progress on cystic fibrosis drug development

17-10-2013

USA-based biotech firm Vertex Pharmaceuticals provided a comprehensive update on recent progress in its…

BiotechnologyKalydecolumacaftorRare diseasesResearchVertexVX-661

Vertex reports fifth consecutive quarter of losses; updates on Kalydeco

30-07-2013

US biotech firm Vertex Pharmaceuticals (Nasdaq: VRTX) has reported second quarter revenues of $311 million,…

FinancialIncivekIncivoKalydecoNorth AmericaPharmaceuticalVertex

Vertex slumps as FDA delays hepatitis C trial

26-07-2013

US drug maker Vertex Pharmaceuticals (Nasdaq: VRTX) saw its shares drop 11% to $78 a share, in after-hours…

Anti-viralsBiotechnologyNorth AmericaPharmaceuticalRegulationResearchVertexVX-135

Vertex shoots up 60% on positive trial results for Kalydeco and VX-661

22-04-2013

US biotech firm Vertex Pharmaceuticals' (Nasdaq: VRTX) shares rocketed 60% to $84.87 Friday morning after…

BiotechnologyKalydecoRare diseasesResearchVertexVX-661

Vertex and Bristol-Myers to trial VX-135 and daclatasvir for hep C; B-MS names new R&D head

08-04-2013

US drugmaker Vertex Pharmaceuticals (Nasdaq: VRTX) has entered into a non-exclusive agreement with pharma…

Anti-viralsBristol-Myers SquibbdaclatasvirManagementPharmaceuticalResearchVertexVX-135

Vertex receives first two Breakthrough Therapy Designations from US FDA

10-01-2013

During its presentation at the JP Morgan annual health care conference, US drugmaker Vertex Pharmaceuticals…

KalydecoNorth AmericaPharmaceuticalRare diseasesRegulationVertexVX-809

Vertex' hep C drug Incivek to carry boxed warning in USA; UK to fund Kalydeco

20-12-2012

US drugmaker Vertex Pharmaceuticals (Nasdaq: VRTX) says that the label on its new hepatitis C drug Incivek…

Anti-viralsEuropeIncivekKalydecoNorth AmericaPharmaceuticalRare diseasesRegulationVertex

Health Canada approves Vertex' Kalydeco; and Sanofi Pasteur's Menactra

03-12-2012

Vertex Pharmaceuticals (Nasdaq: VRTX) says that Health Canada has approved Kalydeco (ivacaftor), the…

BiotechnologyKalydecoMenactraNorth AmericaPharmaceuticalRare diseasesRegulationSanofiSanofi PasteurVaccinesVertex

Canadian scientists' insights into Kalydeco for a rare form of cystic fibrosis

29-10-2012

Scientists at the Hospital for Sick Children in Toronto, Canada, have established that a drug recently…

KalydecoPharmaceuticalRare diseasesResearchRespiratory and PulmonaryVertexVX-770

FDA warns on possible cataract risk with Vertex' Kalydeco

31-08-2012

The US Food and Drug Administration this week notified health care professionals, parents/caregivers…

KalydecoNorth AmericaPharmaceuticalRare diseasesRegulationVertex

EU approval for Eisai's epilepsy drug Fycompa and Vertex' Kalydeco

30-07-2012

Japanese drug major Eisai (TYO: 4523) says that the European Commission has approved for marketing its…

EisaiEuropeFycompaKalydecoNeurologicalPharmaceuticalRare diseasesRegulationVertex

Vertex tumbles despite good final data on combo cystic fibrosis therapy

01-07-2012

USA-based Vertex Pharmaceuticals (Nasdaq: VRTX) saw its shares tumble 16% to $51.18 last week, after…

KalydecoPharmaceuticalRare diseasesResearchRespiratory and PulmonaryVertexVX-809

Incivek and Victrelis important advances in HCV, but still unmet needs

20-06-2012

Nearly two-thirds of US surveyed physicians have seen an increase in the hepatitis C (HCV) patients they…

Anti-viralsIncivekMarkets & MarketingMerck & CoNorth AmericaPharmaceuticalRocheVertexVictrelis

Vertex slumps as firm revises Kalydeco data

30-05-2012

The USA's Vertex Pharmaceuticals (Nasdaq: VRTX) saw its shares plunge 19% to $52.85 in early trading…

KalydecoPharmaceuticalRare diseasesResearchRespiratory and PulmonaryVertex

EMA recommends approval of Vertex' CF drug Kalydeco

28-05-2012

European Medicines Agency last Friday recommended approval of Kalydeco (ivacaftor), an orphan-designated…

EuropeKalydecoPharmaceuticalRare diseasesRegulationRespiratory and PulmonaryVertex

Incivek versus Victrelis in hepatitis C virus treatment: US physician views

10-04-2012

For the treatment of hepatitis C virus (HCV), the majority of surveyed US physicians survey by advisory…

Anti-viralsIncivekMarkets & MarketingMerck & CoNorth AmericaPharmaceuticalRocheVertexVictrelis

2011 financial briefs for Alkermes, Allergan, Gilead and Vertex

03-02-2012

Among the plethora of financial results being reported by US biotech and pharmaceutical companies were…

AlkermesAllerganBiotechnologyFinancialGilead SciencesPharmaceuticalVertex

FDA approves combo diabetes drug Jentadueto and Kalydeco

01-02-2012

The US Food and Drug Administration) has approved Jentadueto (linagliptin/metformin hydrochloride) tablets,…

Boehringer IngelheimDiabetesEli LillyJentaduetoKalydecolinagliptinNorth AmericaPharmaceuticalRare diseasesRegulationVertex

Germany’s IQWiG sees added benefits for Incivo

24-01-2012

In an early benefit assessment pursuant to Germany’s Act on the Reform of the Market for Medicinal…

Anti-viralsEuropeIncivekIncivoJanssenJohnson & JohnsonPharmaceuticalPricingRegulationVertex

1 to 25 of 41 results

Back to top